Pharma & Biotech Global Week in Review 13 October 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. Eisai Co (Orange Book Blog) (FDA Law Blog) (Patently-O)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Media goof up over India-EU ‘settlement’ (Spicy IP) (Spicy IP) (Generic Pharmaceuticals and IP)

Burdened with brackets, biodiversity ABS protocol needs political will to survive (IP Watch)

Brazil: Deposit of microorganism for patents applications (IP tango)

India: Student groups ask for reconsideration of TRIPS-plus provisions of EU-India FTA (Spicy IP)

India: DIPP receives diverse replies to its compulsory licensing policy discussion paper (Spicy IP)

India: An earnest call for responsible reporting (Spicy IP)

US: Institute of Medicine issues report on rare diseases and orphan products; recommends an integrated national strategy (FDA Law Blog)

US: University start-ups and licensing activity held steady during recession (Patent Docs)

US: Contract appeal won’t get to Federal Circuit where infringement is not an issue: Laboratory Corporation of America Holdings v Metabolite Laboratories, Inc (PatLit) (jiplp)

US: One quarter of public biotech companies shut doors since 4Q 2007 (Patent Docs)

Products

Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. Eisai Co (Orange Book Blog) (FDA Law Blog) (Patently-O)

Azilect (Rasagiline) – US: Teva files patent infringement suits against Mylan and Watson in response to Para IV certification (Patent Docs)

Boniva (Ibandronic acid) – US: Roche Boniva patent dispute with Apotex, Cobalt goes to jury (Patent Docs)

Cozaar (Losartan) / Hyzaar (Losartan, Hydrochlorothiazide) – US: It lives!! Apotex asks Supreme Court to review generic Cozaar/Hyzaar 180-day exclusivity decision (FDA Law Blog)

Faslodex (Fulvestrant) – US: AstraZeneca seeks review of BPAI decision concerning patent covering ‘Use of Fulvestrant in treatment of resistant breast cancer’ (Patent Docs)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against Dr Reddy’s following Para IV certification (Patent Docs)

Lipitor (Atorvastatin) – US: Generic LIPITOR – the brass ring of all brass rings for 180-day exclusivity; how will exclusivity resolve? (FDA Law Blog)

Lyrica (Pregabalin) – US: Pfizer files patent infringement suit against Lupin in response to Para IV certification filing (Patent Docs)

Opana (Oxymorphone) – US: Watson reaches settlement with Endo over Opana ER (SmartBrief)

OsmoPrep (Sodium biphosphate, Sodium phosphate) – US: Salix Pharma and Novel Labs settle OsmoPrep patent litigation (Patent Docs)

Sanctura XR (Trospium) – US: Allergan file patent infringement complaints against Paddock Laboratories and Watson Pharmaceuticals in response to Para IV certification (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: